Parkinson's Disease Forecast and Market Analysis to 2035

  • ID: 3797401
  • Report
  • 299 pages
  • Datamonitor Healthcare
1 of 3

Sizable pipeline characterized by both high growth and attrition:

Parkinson’s disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients also experience significant non-motor symptoms including changes in cognition and mood, sleep disturbances, and autonomic dysfunction. The condition is caused by the degeneration of dopamine-producing cells of the substantia nigra. Parkinson’s disease is incurable, but non-fatal, resulting in poor quality of life and increasing disability as the disease progresses. Studies classify Parkinson’s disease as the second most common neurologic disease following Alzheimer’s disease, and it is expected to cause an increasing social and economic burden as populations age.
Recent events and opinion

Parkinson’s disease is predominantly treated with longstanding and mature therapies such as levodopa and the dopamine agonists, pramipexole and ropinirole. The market is therefore dominated by generics, with Teva’s Azilect (rasagiline) being the last lucrative drug indicated for all Parkinson’s disease patients.

Drug developers have responded by introducing new treatment options with clearly defined positions in the market, typically as an option for reducing motor fluctuations alongside levodopa therapy.

The Parkinson’s disease pipeline is characterized by a high level of both growth and attrition. The vast majority of Parkinson’s disease pipeline candidates are in the preclinical stages of development, however, many programs fail to progress into later stages.

Future clinical trials should aim to target a defined patient population. Clinical trials face difficulties including a high placebo response and poor recruitment of patients. The long duration and slow progressive course of the disease are key factors resulting in clinical trials requiring an extensive amount of resources.

READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. FORECAST: PARKINSON’S DISEASE
Executive Summary
Market Overview and Trends
Market Definition and Methodology
Azilect (rasagiline)
CVT-301
Duopa (levodopa/carbidopa)
Neupro (rotigotine)
Nouriast (istradefylline)
Rytary (carbidopa/levodopa)
Stalevo (carbidopa/levodopa/entacapone)
tozadenant
Xadago (safinamide)
Primary Research Methodology

2. TREATMENT: PARKINSON’S DISEASE
Executive Summary
Primary Research Methodology
Disease Definition and Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs in Parkinson’s Disease

3. EPIDEMIOLOGY: PARKINSON’S DISEASE
Executive Summary
Disease Background
Sources and Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations

4. MARKETED DRUGS: PARKINSON’S DISEASE
Executive Summary
Product Overview
Product profile: Apokyn
Product profile: Azilect
Product profile: Duopa
Product profile: Mirapex ER
Product profile: Neupro
Product profile: Nouriast
Product profile: Ongentys
Product profile: Rytary
Product profile: Stalevo
Product profile: Xadago

5. PIPELINE: PARKINSON’S DISEASE
Executive Summary
Clinical Pipeline Overview
Product profile (late stage): APL-130277
Product profile (late stage): CVT-301
Product profile (late stage): ND0612
Product profile (late stage): Nurelin
Product profile (late stage): tozadenant

6. APPENDIX
Appendix: Epidemiology: Parkinson’s Disease

List of Figures:
Figure 1: Parkinson’s disease market sales value in the US, Japan, and five major EU markets ($m), 2014-23
Figure 2: Growth dynamics of the Parkinson’s disease market in the US, Japan, and five major EU markets, 2014-23
Figure 3: Parkinson’s disease market sales value in the US, Japan, and five major EU markets, by class ($m), 2014-23
Figure 4: Parkinson’s disease market sales value in the US, Japan, and five major EU markets, by setting ($m), 2014-23
Figure 5: Leading Parkinson’s disease brands in the US, Japan, and five major EU markets, by sales ($m), 2014-23
Figure 6: Patient-based forecast methodology for Parkinson’s disease
Figure 7: Azilect sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 8: CVT-301 sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 9: Duopa sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 10: Neupro sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 11: Nouriast sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 12: Rytary sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 13: Stalevo sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 14: Tozadenant sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 15: Xadago sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 16: UK Parkinson’s Disease Society Brain Bank criteria
Figure 17: Parkinson’s disease diagnosis rates across the US, Japan, and five major EU markets, by country
Figure 18: Parkinson’s disease progression
Figure 19: Segmentation of respondents’ Parkinson’s disease patients by disease stage in the US, Japan, and five major EU markets, by country
Figure 20: Early-stage Parkinson’s disease patients who fall into each treatment category in the US, Japan, and five major EU markets, by country
Figure 21: Late-stage Parkinson’s disease patients who fall into each treatment category in the US, Japan, and five major EU markets, by country
Figure 22: Mean percentage of patients with early-stage Parkinson’s disease receiving each line of therapy, by country
Figure 23: Top five molecules prescribed for first-line treatment of early-stage Parkinson’s disease, by country
Figure 24: Top five molecules prescribed for second-line and beyond treatment of early-stage Parkinson’s disease, by country
Figure 25: Mean percentage of patients with late-stage Parkinson’s disease receiving each line of therapy across the US, Japan, and five major EU markets, by country
Figure 26: Top five molecules prescribed for first-line treatment of late-stage Parkinson’s disease, by country
Figure 27: Top five molecules prescribed for second-line and beyond treatment of late-stage Parkinson’s disease, by country
Figure 28: Average compliance rates with Parkinson’s disease therapies across the US, Japan, and five major EU markets, by disease subtype and administration route
Figure 29: Key unmet needs in Parkinson’s disease across the US, Japan, and five major EU markets
Figure 30: Trend in diagnosed prevalent cases of Parkinson’s disease in the US, Japan, and five major EU markets, by country, 2015-35
Figure 31: Absolute growth in diagnosed prevalent cases of Parkinson’s disease in the US, Japan, and five major EU markets, by country, 2015-35 153 Figure 32: Age group-specific growth in diagnosed prevalent cases of Parkinson’s disease in the US, Japan, and five major EU markets, 2015-35
Figure 33: Apokyn for Parkinson’s disease - SWOT analysis
Figure 34: Drug assessment summary for Apokyn in Parkinson’s disease
Figure 35: Drug assessment summary for Apokyn in Parkinson’s disease
Figure 36: Azilect for Parkinson’s disease - SWOT analysis
Figure 37: Drug assessment summary for Azilect in Parkinson’s disease
Figure 38: Drug assessment summary for Azilect in Parkinson’s disease
Figure 39: Duopa for Parkinson’s disease - SWOT analysis
Figure 40: Drug assessment summary for Duopa in Parkinson’s disease
Figure 41: Drug assessment summary for Duopa in Parkinson’s disease
Figure 42: Mirapex ER for Parkinson’s disease - SWOT analysis
Figure 43: Drug assessment summary for Mirapex ER in Parkinson’s disease
Figure 44: Drug assessment summary for Mirapex ER in Parkinson’s disease
Figure 45: Neupro for Parkinson’s disease - SWOT analysis
Figure 46: Drug assessment summary for Neupro in Parkinson’s disease
Figure 47: Drug assessment summary for Neupro in Parkinson’s disease
Figure 48: Nouriast for Parkinson’s disease - SWOT analysis
Figure 49: Drug assessment summary for Nouriast in Parkinson’s disease
Figure 50: Drug assessment summary for Nouriast in Parkinson’s disease
Figure 51: Ongentys for Parkinson’s disease - SWOT analysis
Figure 52: Rytary for Parkinson’s disease - SWOT analysis
Figure 53: Drug assessment summary for Rytary in Parkinson’s disease
Figure 54: Drug assessment summary for Rytary in Parkinson’s disease
Figure 55: Stalevo for Parkinson’s disease - SWOT analysis
Figure 56: Drug assessment summary for Stalevo in Parkinson’s disease
Figure 57: Drug assessment summary for Stalevo in Parkinson’s disease
Figure 58: Xadago for Parkinson’s disease - SWOT analysis
Figure 59: Drug assessment summary for Xadago in Parkinson’s disease
Figure 60: Drug assessment summary for Xadago in Parkinson’s disease
Figure 61: APL-130277 for Parkinson’s disease - SWOT analysis
Figure 62: Drug assessment summary for APL-130277 in Parkinson’s disease
Figure 63: Drug assessment summary for APL-130277 in Parkinson’s disease
Figure 64: CVT-301 for Parkinson’s disease - SWOT analysis
Figure 65: Drug assessment summary for CVT-301 in Parkinson’s disease
Figure 66: Drug assessment summary for CVT-301 in Parkinson’s disease
Figure 67: ND0612 for Parkinson’s disease - SWOT analysis
Figure 68: Drug assessment summary for ND0612 in Parkinson’s disease
Figure 69: Drug assessment summary for ND0612 in Parkinson’s disease
Figure 70: Nurelin for Parkinson’s disease - SWOT analysis
Figure 71: Drug assessment summary for Nurelin in Parkinson’s disease
Figure 72: Drug assessment summary for Nurelin in Parkinson’s disease
Figure 73: Tozadenant for Parkinson’s disease - SWOT analysis
Figure 74: Drug assessment summary for tozadenant in Parkinson’s disease
Figure 75: Drug assessment summary for tozadenant in Parkinson’s disease

List of Tables:
Table 1: Parkinson’s disease market sales value in the US, Japan, and five major EU markets ($m), 2014-23
Table 2: Parkinson’s disease market sales value in the US, Japan, and five major EU markets, by class ($m), 2014-23
Table 3: Parkinson’s disease market sales value in the US, Japan, and five major EU markets, by setting ($m), 2014-23
Table 4: Price sources and calculations, by country
Table 5: Exchange rates used for calculating prices
Table 6: Estimated loss of exclusivity dates of key brands in Parkinson’s disease in the US, Japan, and five major EU markets, 2014-23
Table 7: Estimated launch dates of key late-stage pipeline and marketed products in Parkinson’s disease in the US, Japan, and five major EU markets, 2014-23
Table 8: Azilect sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 9: CVT-301 sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 10: Duopa sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 11: Neupro sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 12: Nouriast sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 13: Rytary sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 14: Stalevo sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 15: Tozadenant sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 16: Xadago sales forecast for Parkinson’s disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 17: Neurologists surveyed for the Parkinson’s disease primary research study, 2014
Table 18: Therapies discussed in the Parkinson’s disease key opinion leader primary research study, 2014
Table 19: Neurologists and geriatricians surveyed for the Parkinson’s disease primary research study, 2016
Table 20: Classification of Parkinson’s disease severity according to original five-stage Hoehn and Yahr disability scale
Table 21: Symptoms of Parkinson’s disease
Table 22: Major approved treatments available for Parkinson’s disease across the US, Japan, and five major EU markets
Table 23: Summary of treatment guideline recommendations for the use of varying drug classes for early- and late-stage Parkinson’s disease
Table 24: Parkinson’s disease patients treated with disease-modifying therapy in the US, Japan, and five major EU markets, by country (%)
Table 25: Top 10 regimens prescribed for first-line treatment of early-stage Parkinson’s disease, by country (%)
Table 26: Top 10 regimens prescribed for second-line and beyond treatment of early-stage Parkinson’s disease, by country (%)
Table 27: Top 10 regimens prescribed for first-line treatment of late-stage Parkinson’s disease, by country (%)
Table 28: Top 10 regimens prescribed for second-line and beyond treatment of late-stage Parkinson’s disease, by country (%)
Table 29: Recent high-profile clinical trial failures for the development of neuroprotective therapies in Parkinson’s disease
Table 30: Side effects of commonly used medications in Parkinson’s disease
Table 31: Sources used for Parkinson’s disease analysis in the US, Japan, and five major EU markets
Table 32: Notable sources not used for Parkinson’s disease analysis in the US, Japan, and five major EU markets
Table 33: Comparison of the original and currently used Hoehn and Yahr scales
Table 34: Sources used for estimating Hoehn and Yahr stage distributions in Parkinson’s disease in the US, Japan, and five major EU markets
Table 35: Sources used for estimating the prevalence of co-morbidities in Parkinson’s disease in the US, Japan, and five major EU markets
Table 36: Diagnosed prevalent cases of Parkinson’s disease in the US, Japan, and five major EU markets, by country, 2015-35
Table 37: Age-specific diagnosed prevalent cases of Parkinson’s disease in the US, Japan, and five major EU markets, by country, 2015
Table 38: Gender-specific diagnosed prevalent cases of Parkinson’s disease in the US, Japan, and five major EU markets, by country, 2015
Table 39: Hoehn and Yahr stage distribution of Parkinson’s disease in the US, Japan, and five major EU markets, 2015
Table 40: Diagnosed prevalent cases of Parkinson’s disease in the US, Japan, and five major EU markets, by Hoehn and Yahr stage, 2015
Table 41: Prevalence of co-morbidities in Parkinson’s disease in the US, Japan, and five major EU markets, by co-morbidity, 2015
Table 42: Diagnosed prevalent cases of Parkinson’s disease in the US, Japan, and five major EU markets, by co-morbidity, 2015
Table 43: Key marketed drugs for Parkinson’s disease
Table 44: Apokyn drug profile
Table 45: Apokyn pivotal trial data in Parkinson’s disease
Table 46: Azilect drug profile
Table 47: Azilect pivotal trial data in Parkinson’s disease
Table 48: Duopa drug profile
Table 49: Duopa pivotal trial data in Parkinson’s disease
Table 50: Mirapex ER drug profile
Table 51: Mirapex ER pivotal trial data in Parkinson’s disease
Table 52: Neupro drug profile
Table 53: Neupro pivotal trial data in Parkinson’s disease
Table 54: Nouriast drug profile
Table 55: Nouriast pivotal trial data in Parkinson’s disease
Table 56: Ongentys drug profile
Table 57: Ongentys pivotal trial data in Parkinson’s disease
Table 58: Rytary drug profile
Table 59: Rytary pivotal trial data in Parkinson’s disease
Table 60: Stalevo drug profile
Table 61: Stalevo pivotal trial data in Parkinson’s disease
Table 62: Xadago drug profile
Table 63: Xadago pivotal trial data in Parkinson’s disease
Table 64: Pipeline products in development for Parkinson’s disease
Table 65: APL-130277 drug profile
Table 66: APL-130277 Phase III trials in Parkinson’s disease
Table 67: CVT-301 drug profile
Table 68: CVT-301 Phase III data in Parkinson’s disease
Table 69: ND0612 drug profile
Table 70: ND0612 pivotal trials in Parkinson’s disease
Table 71: Nurelin drug profile
Table 72: Nurelin Phase III data in Parkinson’s disease
Table 73: Tozadenant drug profile
Table 74: Tozadenant pivotal trial data in Parkinson’s disease
Table 75: Tozadenant Phase IIb data in Parkinson’s disease
Table 76: UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll